Study: Naloxone May Not Fully Reverse Synthetic Opioid Overdoses

A new study published in the May 2026 issue of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA), reveals that standard doses of naloxone may not be sufficient to reverse respiratory depression caused by potent synthetic opioids such as fentanyl and sufentanil. The findings, based on research involving 30 participants, indicate that while naloxone remains a lifesaving intervention, a single dose may not always fully restore normal breathing in individuals experiencing overdose from these powerful substances.

Study lead author Maarten A. Van Lemmen, Ph.D., of the Department of Anesthesiology and Anesthesia and Pain Research Unit at Leiden University Medical Center in the Netherlands, emphasized that the reduced effectiveness of naloxone against newer synthetic opioids stems from their stronger binding to opioid receptors. “Our study shows that the current doses of naloxone may not be sufficient to reverse overdoses caused by newer synthetic opioids,” van Lemmen said. “We hope these findings encourage institutions to update guidelines and reinforce the importance of fast emergency intervention.”

The research tested naloxone’s effectiveness in both individuals with no prior opioid use and those who used opioids daily. Results showed that although naloxone can reverse some effects of overdose, it may fail to completely counteract respiratory depression — a critical factor in opioid-related deaths — particularly when high levels or more potent synthetic opioids are involved. This partial reversal can create a dangerous scenario where individuals appear awake and responsive after receiving naloxone but continue to experience inadequate or slow breathing, increasing the risk of resedation and delayed respiratory instability.

Fentanyl and fentanyl-like drugs now account for the majority of overdose deaths in the United States, with estimates ranging from 60% to 79%. Because these substances bind more tightly to opioid receptors than traditional opioids like heroin or morphine, they are harder to displace with standard naloxone dosing. The study authors note that this pharmacological challenge necessitates a reevaluation of current emergency response protocols.

In light of the findings, researchers urge healthcare providers and the public to treat any suspected opioid overdose as a medical emergency requiring immediate activation of emergency services. Even after administering naloxone, individuals should remain under medical observation due to the risk of renewed respiratory depression. The study supports calls for updated clinical guidelines that address dosing strategies, observation practices, and the potential need for multiple naloxone doses in cases involving synthetic opioids.

The study’s authors stress that naloxone remains a vital tool in overdose response and should continue to be widely available. However, they caution against relying solely on a single dose when synthetic opioids are suspected. Instead, they recommend preparing for the possibility of administering additional doses and ensuring rapid transport to emergency care.

As the opioid crisis continues to evolve with the rise of increasingly potent synthetic substances, the study underscores the importance of ongoing research, public education, and adaptive harm reduction strategies. Health officials and medical institutions are encouraged to review current protocols in light of these findings to improve outcomes for individuals experiencing opioid overdose.